Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey ...

Objectives: We evaluated azacitidine ( Vidaza ® ) safety and efficacy in patients with myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML), and chronic myelomonocytic leukaemia (CMML), in a real-life setting. Treatment response, dose, and schedule were assessed. Methods: This non-interventional, post-marketing survey included 49/50 patients receiving azacitidine at 14 Belgian haematology centres from 2010–2012. Treatment-emergent adverse events (TEAEs), including treatment-related TEAEs, and serious TEAEs (TESAEs) were recorded throughout the study. Treatment response [complete respo... Mehr ...

Verfasser: Y. Beguin
D. Selleslag
S. Meers
C. Graux
G. Bries
D. Deeren
I. Vrelust
C. Ravoet
K. Theunissen
V. Voelter
H. Potier
F. Trullemans
L. Noens
P. Mineur
Dokumenttyp: dataset
Erscheinungsdatum: 2019
Verlag/Hrsg.: Taylor & Francis
Schlagwörter: Medicine / Cell Biology / Pharmacology / Immunology / FOS: Clinical medicine / Cancer / Science Policy / Hematology / 60506 Virology / FOS: Biological sciences
Sprache: unknown
Permalink: https://search.fid-benelux.de/Record/base-28885235
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://dx.doi.org/10.6084/m9.figshare.7895333.v1

Objectives: We evaluated azacitidine ( Vidaza ® ) safety and efficacy in patients with myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML), and chronic myelomonocytic leukaemia (CMML), in a real-life setting. Treatment response, dose, and schedule were assessed. Methods: This non-interventional, post-marketing survey included 49/50 patients receiving azacitidine at 14 Belgian haematology centres from 2010–2012. Treatment-emergent adverse events (TEAEs), including treatment-related TEAEs, and serious TEAEs (TESAEs) were recorded throughout the study. Treatment response [complete response (CR), partial response (PR), haematological improvement (HI), stable disease (SD), treatment failure (TF)) and transfusion-independence (TI) were evaluated at completion of a 1-year observation period (1YOP) or at treatment discontinuation, and overall survival (OS), at study conclusion. Results: The median age of patients was 74·7 (range: 43·9–87·8) years; 69·4% had MDS, 26·5% had primary or secondary AML, and 4·1% ...